ARTICLE | Company News

Vernalis, Cancer Research Technology Ltd., The Institute of Cancer Research deal

October 4, 2004 7:00 AM UTC

VER exercised its option, under a 2002 deal, to an exclusive global license for an anti-cancer Hsp90 inhibitor program from Cancer Research Technology and the institute (see BioCentury, April 1, 2002...